Shares fell after the company cut its full-year guidance on the back of challenging macroeconomic conditions and ...

German pharmaceutical and specialty materials group Merck KGaA on Thursday guided more cautiously for 2025 earnings, citing ...

Merck KGaA reduced its outlook for sales and profit growth this year, citing the impact of a weak US dollar and uncertainty ...

By Ludwig Burger FRANKFURT (Reuters) -German pharmaceutical and specialty materials group Merck KGaA on Thursday guided more ...

The US Food and Drug Administration (FDA) has approved belzutifan (Welireg, Merck) for adult and pediatric patients aged 12 ...

Merck’s Keytruda, with more than 40 approved indications, hasn’t yet been able to crack specifically into ovarian cancer. | ...

As has been the case for several quarters now, Merck KGaA’s life science business continues to serve as a weathervane for the ...

Merck will have early-stage opportunities to help startups set up for future success in the pharmaceutical and life sciences fields.

We believe that Merck KGaA enjoys a narrow moat, driven by intangible assets and switching costs which are prevalent in its Life Science and Electronics businesses. A few acquisitions to fill gaps in ...

We recently published a list of 13 Best Cheap Stocks to Invest in for Beginners. In this article, we are going to take a look ...

The U.S. Food and Drug Administration (FDA) on Wednesday approved Merck & Co. Inc.’s (NYSE:MRK) Welireg (belzutifan) for ...